Gastrointestinal Stromal Tumors: Surgical and Medical Therapy

11.

Bonvalot S, Eldweny H, Pechoux CL et al (2006) Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13: 1596–1603PubMedCrossRef

12.

DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51–58PubMedCrossRef

13.

Jeong IH, Kim JH, Lee SR et al (2012) Minimally invasive treatment of gastric gastrointestinal stromal tumors: laparoscopic and endoscopic approach. Surg Laparosc Endosc Percutan Tech 22: 244–50PubMedCrossRef

14.

Novitsky YW, MD, Kercher KW, Sing RF et al (2006) Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 243: 738–747PubMedCrossRef

15.

Nishimura J, Nakajima K, Omori T et al (2007) Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs open resection. Surg Endosc 21: 875–878PubMedCrossRef

16.

Pucci MJ, Berger AC, Lim PW, et al (2012) Laparoscopic approaches to gastric gastrointestinal stromal tumors: an institutional review of 57 cases. Surg Endosc 26: 3509–3514PubMedCrossRef

17.

Furukawa M, Izumi S, Asano H et al (2012) Late umbilical port-site recurrence of a gastrointestinal stromal tumor with an acquired PDGFRα mutation after laparoscopic resection: report of a case. Surg Laparosc Endosc Percutan Tech 22: e109–111PubMedCrossRef

18.

Blay JY, Bonvalot S, Casali P et al (2005) Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16: 566–578PubMedCrossRef

19.

Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet 364: 1127–1134PubMedCrossRef

20.

Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard-versus high-dose imatinibmesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620–625PubMedCrossRef

21.

Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer — Italian Sarcoma Group — Australian Gastrointestinal Trials Group Study. J Clin Oncol 23: 5795–5804PubMedCrossRef

Only gold members can continue reading. Log In or Register to continue